5.6
Cholinergic Receptors: Nicotinic
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in th…
nAChRs are ligand-gated ion channels having a higher affinity for nicotine than ACh or muscarine.
They are classified into NM, or muscle type and NN, or neuronal type.
NM receptors are present at the neuromuscular junction, while NN receptors are present in the autonomic ganglia and the adrenal medulla.
Structurally, nicotinic receptors are rosette-shaped pentamers having a central pore. The pore serves as the ion channel. On the extracellular domain of the receptor, two ACh binding sites are present.
NM receptors comprise alpha, beta, gamma, and delta subunits, whereas NN receptors are composed of only alpha and beta subunits.
Ligand binding to the receptor opens the ion channel to cations such as sodium ions, potassium ions, and calcium ions.
Ion influx depolarizes the end plate, causing either muscle contraction at the neuromuscular junction or nerve impulse continuation at the autonomic ganglia.
View the full transcript and gain access to JoVE Core videos
Q1: What are the two main types of nicotinic receptors and where are they located?
Nicotinic receptors are classified into neuromuscular (NM) and neuronal (NN) types. NM receptors are present at the neuromuscular junction, while NN receptors are located in autonomic ganglia and the adrenal medulla. These two families differ based on their location, subunit composition, and selectivity to agonists and antagonists.
Q2: How does the structure of nicotinic receptors enable ion channel function?
Nicotinic receptors are rosette-shaped pentamers with a central pore that serves as the ion channel. NM receptors comprise alpha, beta, gamma, and delta subunits, while NN receptors contain only alpha and beta subunits. Each subunit has four transmembrane domains surrounding the central pore, allowing cations to pass through when the channel opens.
Q3: Where are acetylcholine binding sites located on nicotinic receptors?
Two acetylcholine binding sites are present on the extracellular domain of nicotinic receptors, located at the interfaces between specific subunits. Ligand binding to these sites triggers a conformational change in the receptor structure, opening the central ion channel and allowing cation movement across the cell membrane.
Q4: What happens when cations flow through nicotinic receptor ion channels?
Cation influx through nicotinic receptors, including sodium, potassium, and calcium ions, depolarizes the cell membrane. At the neuromuscular junction, this depolarization causes muscle contraction. In autonomic ganglia, cation flux enables nerve impulse continuation, allowing signal transmission throughout the nervous system.
Q5: Why do nicotinic receptors have higher affinity for nicotine than acetylcholine?
Nicotinic receptors are ligand-gated ion channels with structural features that preferentially bind nicotine over acetylcholine or muscarine. This differential affinity is determined by the receptor's binding site geometry and chemical interactions. Understanding these selectivity differences is important for developing drugs targeting specific receptor subtypes.
Q6: What is the relationship between nicotinic receptor activation and membrane permeability?
Acetylcholine binding to nicotinic receptors causes a conformational change that opens the ion channel, rapidly increasing cell membrane permeability to potassium, sodium, and calcium ions. This increased permeability allows cation movement down their concentration gradients, leading to membrane depolarization and cellular excitation.
Q7: How do neuromuscular and neuronal nicotinic receptors differ in their subunit composition?
Neuromuscular (NM) receptors contain four different subunit types: alpha, beta, gamma, and delta subunits arranged as pentamers. Neuronal (NN) receptors are composed of only alpha and beta subunits. This structural difference contributes to their distinct pharmacological properties and responses to different agonists and antagonists.